EATG » Scientific research

Scientific research

Promising HIV treatments in late-stage clinical development

Despite the abundance of HIV medications, analysts have identified several unmet needs in the marketplace. Read the full analysis published in P&T Community here.

HIV Research in the Era of PrEP: The Implications of TDF/FTC for Biomedical Prevention Trials

September 27, 2017 – The effectiveness of pre-exposure prophylaxis (PrEP) with the antiretroviral drug combination TDF/FTC (Truvada) raises questions regarding the design and conduct of trials of other candidate biomedical HIV…

Scientists develop a 10-second HIV test linked to mobile phones

Researchers from a group of UK universities have developed a 10-second test for HIV, based on mobile phone technology. The University of Surrey, working with colleagues at University College London,…

Replicor announces publication of its REP 301 study in HBV/HDV co-infection

MONTREAL, September 28, 2017 – Replicor Inc., a privately held biopharmaceutical company targeting a cure for patients with chronic hepatitis B virus (HBV) and chronic HBV and hepatitis delta virus…

The Campbell Foundation awards grant to develop gene editing tool to destroy latent HIV cells in lymph nodes

Sept. 26, 2017 – FORT LAUDERDALE, FL –  The Campbell Foundation, a nonprofit organization dedicated to funding HIV/AIDS research, has awarded an $80,000 grant to Kristine Yoder, PhD, to develop…

Synthetic molecule ‘kicks and kills’ some persistent HIV in mice

New compound shows early promise as potential treatment for dormant HIV infection Scientists have designed a synthetic molecule that can reactivate dormant human immunodeficiency virus (HIV) in mice and lead…

Three-in-one antibody protects monkeys from HIV-like virus

NIH and Sanofi scientists prepare to test antibody in people. A three-pronged antibody made in the laboratory protected monkeys from infection with two strains of SHIV, a monkey form of…

Researchers find a way to reduce HIV replication in the gastrointestinal tract

Researchers at the Université de Montréal Hospital Research Centre (CRCHUM) have discovered a way to slow viral replication in the gastrointestinal tract of people infected by HIV-AIDS. This advance, published…

ABIVAX: First patient dosed in three-month cohort of Phase 2a study of oral ABX464 in HIV-suppressed patients

Trial will evaluate effects of ABX464 on HIV reservoirs in gut tissue and blood Study measures response rate over time PARIS, Sept. 18th, 2017 at 8 a.m. CEST – ABIVAX…

Immunocore and the Bill & Melinda Gates Foundation collaborate to develop immunotherapies for infectious diseases

$40 million investment to accelerate development of Immunocore’s ImmTAV® and ImmTAB® therapeutics for infectious diseases, in particular tuberculosis and HIV (Oxford, UK and Conshohocken, US 18 September 2017) Immunocore Limited,…